| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1036565271 |
| P356 | DOI | 10.1038/BMT.2012.143 |
| P698 | PubMed publication ID | 22863728 |
| P2093 | author name string | Y-B Chen | |
| C S Cutler | |||
| P2860 | cites work | Elafin is a biomarker of graft-versus-host disease of the skin | Q24622918 |
| CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease | Q24644566 | ||
| T-Cell Function and Migration — Two Sides of the Same Coin | Q29041098 | ||
| Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm | Q29547181 | ||
| Lymphocyte homing and homeostasis | Q29619924 | ||
| Leukocyte migration and graft-versus-host disease | Q30479618 | ||
| Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis | Q33244809 | ||
| Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation | Q34156279 | ||
| Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease | Q34663913 | ||
| Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study | Q35909700 | ||
| A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease | Q36363382 | ||
| Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease | Q36615576 | ||
| Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. | Q36835126 | ||
| A biomarker panel for acute graft-versus-host disease | Q37041904 | ||
| Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network | Q37268948 | ||
| Plasma biomarkers in graft-versus-host disease: a new era? | Q37369393 | ||
| Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation | Q40618761 | ||
| Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. | Q40641668 | ||
| Expression of CD30 in patients with acute graft-versus-host disease | Q41984840 | ||
| CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. | Q42518231 | ||
| Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). | Q43485374 | ||
| Increased hepatocyte growth factor in serum in acute graft-versus-host disease | Q43710391 | ||
| A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose. | Q44499725 | ||
| Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial | Q44892383 | ||
| Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. | Q46907591 | ||
| Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation | Q47685290 | ||
| Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation | Q47850193 | ||
| Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation | Q48036095 | ||
| A controlled trial of natalizumab for relapsing multiple sclerosis | Q48414534 | ||
| Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease | Q58814212 | ||
| Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin | Q73002159 | ||
| Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation | Q73432062 | ||
| Increased levels of syndecan-1 in serum during acute graft-versus-host disease | Q73712819 | ||
| Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation | Q73968494 | ||
| Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation | Q73998866 | ||
| Serum cytokine levels after HLA-identical bone marrow transplantation | Q77498884 | ||
| Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation | Q79880337 | ||
| Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation | Q81079571 | ||
| Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation | Q81159555 | ||
| Granzymes A and B serum levels in allo-SCT | Q82950476 | ||
| Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse | Q83071687 | ||
| Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants | Q84192358 | ||
| A prospective study of serum soluble CD30 in allogeneic hematopoietic stem cell transplantation | Q84556038 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 755-760 | |
| P577 | publication date | 2012-08-06 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Biomarkers for acute GVHD: can we predict the unpredictable? | |
| P478 | volume | 48 |
| Q96823744 | A Cancer Biologist's Primer on Machine Learning Applications in High-Dimensional Cytometry |
| Q49806345 | Acute graft-versus-host disease of the gut: considerations for the gastroenterologist |
| Q43976705 | Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts |
| Q38689056 | Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation |
| Q95272135 | Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions |
| Q44550369 | Cellular immune function monitoring after allogeneic haematopoietic cell transplantation: evaluation of a new assay |
| Q34626032 | Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantation |
| Q40053904 | Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation. |
| Q60909733 | Counting circulating endothelial cells in allo-HSCT: an ad hoc designed polychromatic flowcytometry-based panel versus the CellSearch System |
| Q90450386 | Effects of recombinant thrombomodulin therapy and soluble human leukocyte antigen-G levels during hematopoietic stem cell transplantation |
| Q38315390 | Engraftment syndrome: double-edged sword of hematopoietic cell transplants |
| Q37150078 | Evaluation of EPI-X4 as a urinary peptide biomarker for diagnosis and prognosis of late acute GvHD. |
| Q40269737 | Ferritin as an early marker of graft rejection after allogeneic hematopoietic stem cell transplantation in pediatric patients |
| Q52667946 | Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Prediction but Indicates Treatment Safety. |
| Q57817494 | Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects |
| Q37696092 | Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation |
| Q89802490 | Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation |
| Q47561039 | Prediction of absolute risk of acute graft-versus-host disease following hematopoietic cell transplantation. |
| Q87123525 | Soluble interleukin-2 receptor index predicts the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors |
| Q91089808 | The end of omics? High dimensional single cell analysis in precision medicine |
| Q59330598 | Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution |
Search more.